Reported 4 months ago
The article discusses two biotech stocks favored by Cathie Wood, known for her high-risk, high-reward investing style. The first stock is Ginkgo Bioworks (NYSE: DNA), which operates as a biofoundry platform for the biopharma industry. Despite its potential, Ginkgo's financials show significant operating losses, making it a risky investment. The second stock is Recursion Pharmaceuticals (NASDAQ: RXRX), focused on drug discovery using AI. While promising, Recursion is in early-stage trials and has limited revenue compared to its R&D expenses. Both stocks represent high-risk investments, typical of Cathie Wood's portfolio strategy.
Source: YAHOO